Insight

Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology

Photo of Ankit Mangla taken from X/Twitter

Apr 2, 2024, 12:20

Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology

Ankit Mangla, Sarcoma and Cutaneous Oncology Specialist at the Seidman Cancer Center, shared a post by JAMA Oncology on X/Twitter, adding:

“Hot off the press. Our analysis of data from neoadjuvant IO trials in melanoma published in JAMA Oncology. The phenomenal John M. Kirkwood mentored our team to develop this paper. Ipi3-nivo1 or ipi1-nivo3 or anti-pd1- which one to give? We provide some answers in this paper.”

Quoting JAMA Oncology’s paper:

“A pooled analysis of six clinical trials shows that while the odds of a favorable pathologic and radiologic response are high, the risk of adverse events is high with dual checkpoint inhibitors in resectable high-risk melanoma compared to anti-PD1 alone.”

Source: Ankit Mangla/X and JAMA Oncology/X

analysis Ankit Mangla anti-pd1 cancer checkpoint inhibitors clinical trials IO trials ipi1-nivo3 Ipi3-nivo1 JAMA Oncology John M. Kirkwood Melanoma OncoDaily Oncology paper pathological response radiological response

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage